Volume 107, Issue 1 pp. 139-144
Epidemiology

Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: A case-control study in Japanese nonsmoking women

Chikako Kiyohara

Corresponding Author

Chikako Kiyohara

Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Fax: +81-092-642-6115

Department of Preventive Medicine, Division of Social Medicine, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka 812-8582, JapanSearch for more papers by this author
Kenji Wakai

Kenji Wakai

Department of Preventive Medicine/Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Nagoya, Japan

Search for more papers by this author
Haruo Mikami

Haruo Mikami

Division of Epidemiology, Chiba Cancer Research Institute, Chiba, Japan

Search for more papers by this author
Koichi Sido

Koichi Sido

Health Sciences University of Hokkaido, Graduate School of Nursing and Social Services, Department of Social Work and Clinical Psychology, Hokkaido, Japan

Search for more papers by this author
Masahiko Ando

Masahiko Ando

Kyoto University Center for Student Health, Kyoto, Japan

Search for more papers by this author
Yoshiyuki Ohno

Yoshiyuki Ohno

Department of Preventive Medicine/Biostatistics and Medical Decision Making, Nagoya University Graduate School of Medicine, Nagoya, Japan

Search for more papers by this author
First published: 13 August 2003
Citations: 46

Abstract

Genetic backgrounds may modify the association of environmental tobacco smoke (ETS) with lung cancer risk. Polymorphisms of both the activating and detoxifying enzymes, cytochrome P4501A1 (CYP1A1) and glutathione-S-transferase M1 (GSTM1), may be important as genetic factors. We conducted a multicenter case-control study in Japanese nonsmoking women. Cases were women aged 30–89 years and newly diagnosed as having lung cancer from November 1997 to March 2001 in 4 study areas. We also recruited age-matched (5-year strata) and hospital-matched nonsmoking controls. A total of 158 cases and 259 hospital controls supplied blood for genotyping. Detailed information on ETS exposure from husbands and that in other situations and on potential confounders was collected by interview. Odds ratios (ORs) were estimated by using conditional logistic models. We found no increase in the risk of lung cancer for CYP1A1 Msp I genotypes. For the GSTM1 null genotype vs. nonnull genotype, the OR was 1.37 [95% confidence interval (CI) 0.90–2.09], which indicated a somewhat increased risk for the GSTM1 null genotype. A gene-environment interaction was suggested, with combined GSTM1 null genotype and high-dose ETS exposure (≥40 pack-years by husbands) conferring significantly higher risk (OR = 2.27, 95% CI 1.13–4.57) compared to the GSTM1 nonnull genotype and low-dose ETS exposure (<40 pack-years). Our results do not support a major role of Msp I polymorphism of the CYP1A1 gene as a risk factor for lung cancer among nonsmoking women. In contrast, the GSTM1 null genotype posed an increased, although not significant, risk among them. Additional studies are warranted to confirm the ETS-GSTM1 polymorphism interaction suggested in our present study. © 2003 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.